Skip to main content
Signal8

BioAtla, Inc. (BCAB)

BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer. A third candidate, BA3071, is a conditionally active anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody aimed at a broad spectrum of cancers, including renal cell carcinoma, non-small cell and small cell lung cancers, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. Established in 2007, BioAtla Inc. operates out of San Diego, California.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

BioAtla, Inc. logo

BioAtla, Inc.

OTC:BCABOTC (suspended from Nasdaq on Aug 31, 2026)Healthcare
AH+0.00%$1.80
Close$1.80-9.55%
Mkt Cap-
EV-
Float1.55M
O/S-
VOL3K sh
$ Vol$6K
RVOL0.47×
Inst Own6.5%
Net Cash/Sh-
Dilution
BioAtla, Inc. logoOTC:BCABAH$1.80+0.00%
  • AI analysis ›